OncoMatch/Clinical Trials/NCT05198830
Testing the Addition of an Anti-Cancer Drug, TRC102, to the Usual Chemotherapy Treatment (Pemetrexed, Cisplatin or Carboplatin) During Radiation Therapy for Stage III Non-Squamous Non-Small Cell Lung Cancer
Is NCT05198830 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies multiple treatments for lung adenocarcinoma.
Treatment: Carboplatin · Cisplatin · Durvalumab · Methoxyamine · Pemetrexed — This phase II trial tests whether TRC102 (methoxyamine hydrochloride) in combination usual care treatment comprised of pemetrexed, cisplatin or carboplatin, and radiation therapy followed by durvalumab works better than the usual care treatment alone to shrink tumors in patients with stage III non-squamous non-small cell lung cancer (NSCLC). TRC102 is in a class of drugs called antineoplastic agents. It blocks the ability of a cell to repair damage to its deoxyribonucleic acid (DNA) and may kill tumor cells. It may also help some anticancer drugs work better. Pemetrexed is in a class of medications called antifolate antineoplastic agents. It works by stopping cells from using folic acid to make DNA and may kill tumor cells. Cisplatin is in a class of medications known as platinum-containing compounds. It works by killing, stopping or slowing the growth of tumor cells. Carboplatin is in a class of medications known as platinum-containing compounds. It works in a way similar to the anticancer drug cisplatin, but may be better tolerated than cisplatin. Carboplatin works by killing, stopping or slowing the growth of tumor cells. Immunotherapy with monoclonal antibodies, such as durvalumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Radiation therapy uses high energy sources to kill tumor cells and shrink tumors. Giving TRC102 in combination with usual care treatment may be more effective than usual care treatment alone in stabilizing and lengthening survival time in patients with stage III non-squamous NSCLC.
Check if I qualifyExtracted eligibility criteria
Cancer type
Non-Small Cell Lung Carcinoma
Biomarker criteria
Required: ALK wild-type
Required: EGFR wild-type
Disease stage
Required: Stage IIIA, IIIB, IIIC
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Cannot have received: investigational agent
Patients who are receiving any other investigational agents.
Lab requirements
Blood counts
Leukocytes >= 3,000/mcL; Hemoglobin >= 9.0 g/dL; Absolute neutrophil count >= 1,500/mcL; Platelets >= 150,000/mcL
Kidney function
Creatinine <= 1.3 mg/dL; measured creatinine clearance >= 60 mL/min OR GFR >= 50 mL/min/1.73 m^2
Liver function
Serum bilirubin within normal institutional limits (0 - 1.2 mg/dL); AST <= 2.5 x ULN (<= 39 U/L); ALT <= 2.5 x ULN (<= 52 U/L)
Cardiac function
NYHA class 2B or better if cardiac history or risk
Leukocytes >= 3,000/mcL. Hemoglobin >= 9.0 g/dL. Absolute neutrophil count >= 1,500/mcL. Platelets >= 150,000/mcL. Serum bilirubin within normal institutional limits (0 - 1.2 mg/dL). AST <= 2.5 x ULN (<= 39 U/L). ALT <= 2.5 x ULN (<= 52 U/L). Creatinine <= 1.3 mg/dL. Measured creatinine clearance >= 60 mL/min OR GFR >= 50 mL/min/1.73 m^2. Acceptable pulmonary function as assessed by treating physician. ... cardiac risk assessment ... NYHA class 2B or better.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Keck Medicine of USC Buena Park · Buena Park, California
- City of Hope Comprehensive Cancer Center · Duarte, California
- City of Hope at Irvine Lennar · Irvine, California
- City of Hope Antelope Valley · Lancaster, California
- Los Angeles General Medical Center · Los Angeles, California
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify